Background: An insulin with a significantly faster onset of action compared to current state-of-the-art products will improve postprandial glycaemic control, reduce variability, improve HbA1c and increase flexibility. A superfast insulin is a key component for the development of efficient closed-loop pump systems.

Method: A superfast formulation, utilising excipients with metal ion binding constants critical in controlling injection site absorption, was investigated in diabetic mini swine in a randomized, cross-over experiment. Ten male animals received 0.2 U/kg insulin via subcutaneous injection. At standardized intervals post-injection, blood glucose and insulin were measured.

Results: Pharmacodynamic (PD) and pharmacokinetic (PK) properties of Superfast insulin were compared to an ultra-rapid control composition including nicotinamide. Tmax (22.5 minutes vs. 41.9 minutes) and T1/2max (7.9 minutes vs. 11.9 minutes) were significantly (P<0.01 and P<0.02) shorter for Superfast insulin, with a correspondingly faster glucose lowering action (Figure 1). Figure 1a) PD and 1b) PK profile of 100U/mL Superfast insulin (red) in comparison to an ultra-rapid acting insulin control containing nicotinamide (blue)1a.

Conclusion: This novel formulation represents a unique superfast prandial insulin that more closely matches a physiological response to blood glucose with the potential to be a major advancement for diabetes care.


T.R. Pieber: Consultant; Self; Arecor, AstraZeneca, Eli Lilly and Company, Novo Nordisk A/S, Sanofi. Employee; Self; CBmed. Research Support; Self; Novo Nordisk A/S, AstraZeneca. S.J. Howell: None. J. Jezek: None. D.J. Gerring: Employee; Self; Arecor Limited.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at